KALARIS THERAPEUTICS, INC. Impairment of Long-Lived Assets Held-for-use
KALARIS THERAPEUTICS, INC. (KLRS) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-03-07
- KALARIS THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $500.00K.
- KALARIS THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- KALARIS THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-07 |
| 2023-12-31 | $500.00K 10-K · filed 2024-03-15 |
| 2022-12-31 | $0.00 10-K · filed 2023-02-15 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-15 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-10 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |